header logo image


Page 1,100«..1020..1,0991,1001,1011,102..1,1101,120..»

Roche won’t sell diabetes businessit’s looking for deals to boost it instead – FierceBiotech

February 6th, 2017 9:46 am

A week after Johnson & Johnson said it was weighing strategic options for its diabetes device divisions, reports emerged that Roche was doing the same with its diabetes testing unit. But diagnostics chief Roland Diggelman put an end to speculation Wednesday, saying the Swiss company wants to expand the biz, Reuters reported.

Bloomberg reported Tuesday that people familiar with the matter said Roche was considering options for its diabetes care unit, including a spinoff or a sale.

Roches diabetes care sales dropped 4% in FY 2016, thanks to pricing pressure in the U.S. But Diggelmann dismissed reports the company was considering a sale, Reuters reported. In fact, he said, the company is on the prowl for new tech that could boost the flagging business.

"We basically have all of the technologies we need in-house in varying degrees of development, so we have to ask ourselves, 'How far are we along?'" Diggelmann said, as quoted by Reuters "We're looking around: Are there new possibilities, are there alternatives?"

Roche faced similar speculation in 2015, after Bayer sold off its diabetes device unit to KKR/Panasonic. But while Roches diabetes business had had a rough couple of years, thanks

To price cuts in the U.S., Diggelmann said at the time: "It's still a good business and a business with a future.

The company markets the Accu-Chek line of devices, which includes blood glucose meters and insulin pumps. It leads the diabetes testing industry, ahead of competitors J&J, Abbott and KKR/Panasonic.

In May last year, Roche Diabetes Care inked a deal with Senseonics to sell the latters Eversense Continuous Glucose Monitoring System in Germany, Italy and the Netherlands. Senseonics system comprises a rice-sized sensor that is implanted just under the skin and measures blood glucose levels for 90 days.

Read the original post:
Roche won't sell diabetes businessit's looking for deals to boost it instead - FierceBiotech

Read More...

Diabetes May Be Warning Sign of Pancreatic Cancer – WebMD

February 6th, 2017 9:46 am

Jan. 31, 2017 -- Diabetes could be an early sign of pancreatic cancer, new research suggests.

A presentation to the European Cancer Congress in Amsterdam reports that 50% of people in two sample groups who had been diagnosed with pancreatic cancer had been diagnosed with type 2 diabetes in the previous year and been given their first medication to control it.

Fewer than 5 out of 100 people can expect to be alive 5 years after being diagnosed with pancreatic cancer. Survival rates are poor because the cancer doesn't usually cause any symptoms until late in the disease.

The American Cancer Society estimates more than 53,000 people will be diagnosed with pancreatic cancer in 2017.

"Although it has been known for some time that there is an association between type 2 diabetes and pancreatic cancer, the relationship between the two conditions is complex," Alice Koechlin, from the International Prevention Research Institute in Lyon, France, told the conference.

The pancreas contains cells that make insulin. Type 2 diabetes happens when these cells are unable to make enough insulin or the insulin doesn't work properly.

The study involved 368,377 people with type 2 diabetes in Belgium and 456,311 in Italy.

Among these patients over a 5-year period, there were 885 and 1,872 cases of pancreatic cancer diagnosed respectively.

The researchers found that patients had a 3.5 times higher risk of being diagnosed with pancreatic cancer compared to those on other non-insulin, non-incretin diabetes treatments in the first 3 months after their first prescription for a class of diabetes medications known as incretins. The risks decreased with time. These are hormones that stimulate the pancreas to produce more insulin.

Among patients who already had type 2 diabetes, the need to switch to injecting insulin because their condition got worse was associated with a seven-times-higher risk of being diagnosed with pancreatic cancer.

"Doctors and their diabetic patients should be aware that the onset of diabetes or rapidly deteriorating diabetes could be the first sign of hidden pancreatic cancer, and steps should be taken to investigate it," Koechlin said.

"The association between pancreatic cancer and type 2 diabetes has been an area of interest to researchers for several years, so its great to see studies generating new and potentially very valuable information which could alert clinicians to the need for further investigation in certain patients, said Maggie Blanks, chief executive of the Pancreatic Cancer Research Fund, in a statement.

"We now need the work developing early diagnostic tests to catch up so that we can make use of this information as soon as possible. There are global efforts investigating biomarkers for pancreatic cancer in blood or saliva that may have diagnostic potential and the early research that PCRF has funded which identified biomarkers in urine is progressing towards a clinical trial.

"We may well be on the cusp of a significant improvement in both identifying those at higher risk and being able to diagnose quickly, so that appropriate treatment can start as soon as possible."

These findings were presented at a medical conference. They should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.

SOURCES:

2017 European Cancer Congress: "Early detection of pancreatic cancer among diabetic patients: results from prescription database analyses."

European Cancer Organisation.

Pancreatic Cancer Research Fund.

American Cancer Society.

Read the rest here:
Diabetes May Be Warning Sign of Pancreatic Cancer - WebMD

Read More...

Study: Death likely within 5 years of loss of smell | KXAN.com – KXAN.com

February 6th, 2017 9:45 am

KXAN.com
Study: Death likely within 5 years of loss of smell | KXAN.com
KXAN.com
If you think you are losing your sense of smell, or have a family member who is, doctors say it needs to be checked out.

and more »

Original post:
Study: Death likely within 5 years of loss of smell | KXAN.com - KXAN.com

Read More...

To fulfill stem cell agency’s promise, consider winding it down – Sacramento Bee

February 6th, 2017 9:45 am

Sacramento Bee
To fulfill stem cell agency's promise, consider winding it down
Sacramento Bee
The stem cell agency, in fact, recently failed to raise just $75 million in new funds from private investors. Even if all stem cell clinical trials resulted in drug candidates, they would still come up against the so-called Valley of Death the term ...

Here is the original post:
To fulfill stem cell agency's promise, consider winding it down - Sacramento Bee

Read More...

Unraveling the mystery of why cancer cells survive and thrive – Science Daily

February 6th, 2017 9:45 am

Some cancer cells have a trick up their sleeve to avoid cell death: boosting maintenance of telomeres, the protective "end caps" on chromosomes, and a research team led by Jackson Laboratory (JAX) Professor Roel Verhaak reports in Nature Genetics on a newly discovered telomere maintenance mechanism.

The findings open avenues for functional studies that may yield insight into how to steer cancer cells away from immortalizing and back to normal death programming. Moreover, harnessing telomere maintenance mechanisms could be a potential approach to selectively retarding aging. The 2009 Nobel Prize in Physiology or Medicine to Elizabeth Blackburn, Carol Greider and Jack Szostak established the roles of telomeres and telomerase in the aging of cells and organisms.

In most cells, telomeres shorten over time to the point where cell division is no longer possible, leading to cell death. Certain cells, such as stem cells and germ cells, are capable of ongoing division because they contain active telomerase, an enzyme that lengthens telomeres.

It has been long known to researchers that cancer cells reactivate telomerase through telomerase reverse transcriptase (TERT) transcription, but the mechanisms behind this remain elusive.

"These cancer cells are hijacking a mechanism to maintain telomeres, enabling them to continue to divide," Verhaak says.

The researchers scanned 18,430 samples from cancerous and non-neoplastic tissues to determine and compare their telomere lengths and query them for telomerase activity. The analysis, which included samples from 31 different cancer types, showed that telomeres were generally shorter in tumors than in healthy tissues, and longer in soft tissue tumors and brain tumors compared to other cancers.

They found that the majority -- 73 percent -- of cancers expressed TERT (which in turn drives reactivation of telomerase). In addition to the expected mutations and genomic rearrangements driving TERT expression, the researchers discovered an important new mechanism: TERT promoter methylation.

In methylation, clumps of molecules called methyl groups attach to a segment of DNA and can change the activity of that segment without changing its genetic sequence.

Methylation in DNA sequences known as promoters, as the researchers found in most of the cancer samples, typically acts to repress gene transcription, the process of making an RNA copy of a gene sequence. Counterintuitively, Verhaak says, "we found that TERT DNA promoter methylation resulted in TERT expression. We think that because of the DNA methylation, mRNA transcription-repressing proteins are no longer able to bind."

About 22 percent of the tumor cells lacked detectable TERT expression. "There could be a number of reasons for this," says Floris Barthel, a JAX postdoctoral associate and first author of the study. "Maybe not all tumors harbor immortalized cells with a telomere maintenance mechanism, or there are alternative mechanisms at play, or perhaps TERT expression that falls below the detection threshold we used is still sufficient to maintain telomeres." Future studies are needed to elucidate the telomere maintenance mechanisms, or lack thereof, in these tumors, he notes.

Story Source:

Materials provided by Jackson Laboratory. Original written by Joyce Dall'Acqua Peterson. Note: Content may be edited for style and length.

View original post here:
Unraveling the mystery of why cancer cells survive and thrive - Science Daily

Read More...

Blindness (film) – Wikipedia

February 6th, 2017 9:45 am

Blindness is a 2008 Brazilian-Canadian film, an adaptation of the 1995 novel of the same name by Portuguese author Jos Saramago about a society suffering an epidemic of blindness. The film was written by Don McKellar and directed by Fernando Meirelles with Julianne Moore and Mark Ruffalo as the main characters. Saramago originally refused to sell the rights for a film adaptation, but the producers were able to acquire it with the condition that the film would be set in an unnamed and unrecognizable city. Blindness premiered as the opening film at the Cannes Film Festival on May 14, 2008, and the film was released in the United States on October 3, 2008.

A young Japanese professional is struck blind in his car at a crossing and is then approached by a few people, one offers to drive him home and steals his car. The blinded man describes his sudden affliction: an expanse of dazzling white. Upon arriving home and noticing her husband's blindness, the man's wife takes him to a local ophthalmologist who, after testing the man's eyes, can identify nothing wrong and recommends further evaluation at a hospital. Among the doctor's patients are an old man with a black eye-patch, a woman with dark glasses and a young boy. During a dinner with his wife, the doctor discusses the strange case. The woman with dark glasses, revealed to be a call-girl, becomes the third victim of the strange blindness after an appointment with a john in a hotel.

The next day, the doctor goes blind as well. Around the city, more citizens are struck blind, causing widespread panic, and the government organizes a quarantine for the blind in a derelict asylum. When a hazmat crew arrives to pick up the doctor, his wife climbs into the van, lying that she has gone blind in order to accompany him.

In the asylum, the doctor and his wife are first to arrive and both agree they will keep her sight a secret. Several others arrive: the woman with dark glasses, the Japanese man, the car thief, and the young boy. The wife comes across the old man with the eye-patch, who describes the condition of the world outside. The sudden blindness, known as the "white sickness", is now international, with hundreds of cases reported every day. The increasingly totalitarian government resorts to increasingly ruthless measures to try to staunch the epidemic, refusing the sick aid or medicines.

As more blind people are crammed into the prison, overcrowding and lack of outside support causes hygiene and living conditions to degrade. Soon, the walls and floors are caked in filth and human feces. Anxiety over the availability of food undermines the morale and the lack of organization prevents the fair distribution of food. The soldiers who guard the asylum become hostile.

Living conditions degenerate further when an armed clique of men, led by an ex-barman who declares himself the king of ward 3 gains control over the food deliveries. The MRE rations are distributed only in exchange for valuables, and then for the women of the other wards. Faced with starvation, the doctor's wife kills the king. His death initiates a chaotic war between the wards, which culminates with the asylum being burned down and many inmates dying in the fire. The survivors discover that the guards have abandoned their posts and they are free to venture into the city.

Society has fallen as the entire population is blind amid a city devastated and overrun with filth and dead bodies. The doctor's wife leads her husband and others in search of food and shelter. The doctor and his wife arrive in a supermarket filled with stumbling blind people and they find food in a basement storeroom. As she prepares to leave and meet her husband outside, she is attacked by the starving people who smell the food she is carrying. Her husband, now used to his blindness, saves her and they manage to return to their friends.

The doctor and his wife with their new "family" make their way back to the doctor's house, where they establish a permanent home. Just as suddenly as his sight had been lost, the Japanese man recovers his sight. As the friends all celebrate, the doctor's wife stands out on the porch, staring up into a white overcast sky and appears to be going blind until the camera shifts downwards, revealing that she sees the cityscape.

Secondary characters include:

Meirelles chose an international cast. Producer Niv Fichman explained Meirelles' intent: "He was inspired by [Saramago's] great masterwork to create a microcosm of the world. He wanted it cast in a way to represent all of humanity."[10]

The rights to the 1995 novel Blindness were closely guarded by author Jos Saramago.[6] Saramago explained, "I always resisted because it's a violent book about social degradation, rape, and I didn't want it to fall into the wrong hands." Director Fernando Meirelles had wanted to direct a film adaptation in 1997, perceiving it as "an allegory about the fragility of civilization". Saramago originally refused to sell the rights to Meirelles, Whoopi Goldberg, or Gael Garca Bernal.[11] In 1999, producer Niv Fichman and Canadian screenwriter Don McKellar visited Saramago in the Canary Islands; Saramago allowed their visit on condition that they not discuss buying the rights. McKellar explained the changes he intended to make from the novel and what the focus would be, and two days later he and Fichman left Saramago's home with the rights. McKellar believed they had succeeded where others had failed because they properly researched Saramago; he was suspicious of the film industry and had therefore resisted other studios' efforts to obtain the rights through large sums of money alone.[12] Conditions set by Saramago were for the film to be set in a country that would not be recognizable to audiences,[13] and that the canine in the novel, the Dog of Tears, should be a big dog.[14]

Meirelles originally envisioned doing the film in Portuguese similar to the novel's original language, but instead directed the film in English, saying, "If you do it in English you can sell it to the whole world and have a bigger audience."[9] Meirelles set the film in a contemporary large city, seemingly under a totalitarian government, as opposed to the novel that he believed took place in the 1940s (actually, the book is more likely to take place in the 80s or later, as evident by the fact that the characters stumble upon a store with modern appliances like microwave ovens and dishwashers, and referral to AIDS as a feared disease). Meirelles chose to make a contemporary film so audiences could relate to the characters.[14] The director also sought a different allegorical approach. He described the novel as "very allegorical, like a fantasy outside of space, outside the world", and he instead took a naturalistic direction in engaging audiences to make the film less "cold."[15]

Don McKellar said about adapting the story, "None of the characters even have names or a history, which is very untraditional for a Hollywood story. The film, like the novel, directly addresses sight and point of view and asks you to see things from a different perspective." McKellar wrote the script so audiences would see the world through the eyes of the protagonist, the doctor's wife. He sought to have them question the humanity of how she observes but does not act in various situations, including a rape scene. He consulted Saramago about why the wife took so long to act. McKellar noted, "He said she became aware of the responsibility that comes with seeing gradually, first to herself, then to her husband, then to her small family, then her ward, and finally to the world where she has to create a new civilization." The screenwriter wrote out the "actions and circumstances" that would allow the wife to find her responsibility.[5] While the completed script was mostly faithful to the novel, McKellar went through several drafts that were not. One such saw him veer away from the novel by creating names and backstories for all the characters. Another significantly changed the chronology. Only after these abortive attempts did McKellar decide to cut the backstories and focus primarily on the doctor and his wife. He attempted to reconnect with what originally drew him to the novel: what he called its "existential simplicity". The novel defines its characters by little more than their present actions; doing the same for the adaptation became "an interesting exercise" for McKellar.[12]

McKellar attended a summer camp for the blind as part of his research. He wanted to observe how blind people interacted in groups. He discovered that excessive expositional dialogue, usually frowned upon by writers, was essential for the groups. McKellar cut one of the last lines in the novel from his screenplay: "I don't think we did go blind, I think we are blind. Blind but seeing. Blind people who can see, but do not see." McKellar believed viewers would by that point have already grasped the symbolism and didn't want the script to seem heavy-handed. He also toned down the visual cues in his screenplay, such as the "brilliant milky whiteness" of blindness described in the novel. McKellar knew he wanted a stylistically adept director and didn't want to be too prescriptive, preferring only to hint at an approach.[12]

Meirelles chose So Paulo as the primary backdrop for Blindness, though scenes were also filmed in Osasco, Brazil; Guelph, Ontario, Canada; and Montevideo, Uruguay. With all the characters aside from Julianne Moore's character being blind, the cast was trained to simulate blindness. The director also stylized the film to reflect the lack of point of view that the characters would experience. Meirelles said several actors he talked to were intimidated by the concept of playing characters without names: "I offered the film to some actors who said, 'I can't play a character with no name, with no history, with no past. With Gael (Garca Bernal), he said, 'I never think about the past. I just think what my character wants.'"[16]

By September 2006, Fernando Meirelles was attached to Blindness, with the script being adapted by Don McKellar. Blindness, budgeted at $25 million as part of a Brazilian and Canadian co-production, was slated to begin filming in summer 2007 in the towns of So Paulo and Guelph.[17] Filming began in early July in So Paulo and Guelph.[18] Filming also took place in Montevideo, Uruguay.[19] So Paulo served as the primary backdrop for Blindness, being a city mostly unfamiliar to U.S. and European audiences. With its relative obscurity, the director sought So Paulo as the film's generic location. Filming continued through autumn of 2007.[6]

The cast and crew included 700 extras who had to be trained to simulate blindness. Actor Christian Duurvoort from Meirelles' City of God led a series of workshops to coach the cast members. Duurvoort had researched the mannerisms of blind people to understand how they perceive the world and how they make their way through space. Duurvoort not only taught the extras mannerisms, but also to convey the emotional and psychological states of blind people.[6] One technique was reacting to others as a blind person, whose reactions are usually different from those of a sighted person. Meirelles described, "When you're talking to someone, you see a reaction. When you're blind, the response is much flatter. What's the point [in reacting]?"[20]

Meirelles acknowledged the challenge of making a film that would simulate the experience of blindness to the audience. He explained, "When you do a film, everything is related to point of view, to vision. When you have two characters in a dialogue, emotion is expressed by the way people look at each other, through the eyes. Especially in the cut, the edit. You usually cut when someone looks over. Film is all about point of view, and in this film there is none."[20] Similar to the book, blindness in the film serves as a metaphor for human nature's dark side: "prejudice, selfishness, violence and willful indifference."[6]

With only one character's point of view available, Meirelles sought to switch the points-of-view throughout the film, seeing three distinct stylistic sections. The director began with an omniscient vantage point, transited to the intact viewpoint of the doctor's wife, and changed again to the Man with the Black Eye Patch, who connects the quarantined to the outside world with stories. The director concluded the switching with the combination of the perspective of the Doctor's Wife and the narrative of the Man with the Black Eye Patch.[5]

The film also contains visual cues, such as the 1568 painting The Parable of the Blind by Pieter Bruegel the Elder. Allusions to other famous artworks are also made. Meirelles described the intent: "It's about image, the film, and vision, so I thought it makes sense to create, not a history of painting, because it's not, but having different ways of seeing things, from Rembrandt to these very contemporary artists. But it's a very subtle thing."[6]

Prior to public release, Meirelles screened Blindness to test audiences. He described the impact of test screenings: "If you know how to use it, how to ask the right questions, it can be really useful." A test screening of Meirelles' first cut in Toronto resulted in ten percent of the audience, nearly 50 people, walking out of the film early. Meirelles ascribed the problem to a rape scene that takes place partway through the film, and edited the scene to be much shorter in the final cut.[21] Meirelles explained his goal, "When I shot and edited these scenes, I did it in a very technical way, I worried about how to light it and so on, and I lost the sense of their brutality. Some women were really angry with the film, and I thought, 'Wow, maybe I crossed the line.' I went back not to please the audience but so they would stay involved until the end of the story."[9] He also found that a New York City test screening expressed concern about a victim in the film failing to take revenge. Meirelles believed this concern to reflect what Americans have learned to expect in their cinema.[21]

Focus Features acquired the right to handle international sales for Blindness.[22]Path acquired UK and French rights to distribute the film,[23] and Miramax Films won U.S. distribution rights with its $5 million bid.[24]Blindness premiered as the opening film at the 61st Cannes Film Festival on May 14, 2008,[25] where it received a "tepid reception."[26] Straw polls of critics were "unkind" to the film.[27]

Blindness was screened at the Toronto International Film Festival in September 2008 as a Special Presentation.[28] The film also opened at the Atlantic Film Festival on September 11, 2008,[29] and had its North American theatrical release on October 3, 2008.

The film was on some critics' top ten lists of 2008 films but has received very mixed, predominantly negative reviews. With only 66 of 153 (43%) reviews on the film review site Rotten Tomatoes being positive Blindness is considered "rotten". The film has an average rating of 5.2 out of 10.[30]

Screen International's Cannes screen jury which annually polls a panel of international film critics gave the film a 1.3 average out of 4, placing the film on the lower-tier of all the films screened at competition in 2008.[31] Of the film critics from the Screen International Cannes critics jury, Alberto Crespi of the Italian publication L'Unit, Michel Ciment of French film magazine Positif and Dohoon Kim of South Korean film publication Cine21, all gave the film zero points (out of four).[31]

Kirk Honeycutt of The Hollywood Reporter described Blindness as "provocative but predictable cinema", startling but failing to surprise. Honeycutt criticized the film's two viewpoints: Julianne Moore's character, the only one who can see, is slow to act against atrocities, and the behavior of Danny Glover's character comes off as "slightly pompous". Honeycutt explained, "This philosophical coolness is what most undermines the emotional response to Meirelles' film. His fictional calculations are all so precise and a tone of deadly seriousness swamps the grim action."[32] Justin Chang of Variety described the film: "Blindness emerges onscreen both overdressed and undermotivated, scrupulously hitting the novel's beats yet barely approximating, so to speak, its vision." Chang thought that Julianne Moore gave a strong performance but did not feel that the film captured the impact of Saramago's novel.[33]Roger Ebert called Blindness "one of the most unpleasant, not to say unendurable, films I've ever seen."[34]A. O. Scott of The New York Times stated that, although it "is not a great film, ... it is, nonetheless, full of examples of what good filmmaking looks like."[35]

Stephen Garrett of Esquire complimented Meirelles' unconventional style: "Meirelles [honors] the material by using elegant, artful camera compositions, beguiling sound design and deft touches of digital effects to accentuate the authenticity of his cataclysmic landscape." Despite the praise, Garrett wrote that Meirelles' talent at portraying real-life injustice in City of God and The Constant Gardener did not suit him for directing the "heightened reality" of Saramago's social commentary.[36]

Peter Bradshaw of The Guardian called it "an intelligent, tightly constructed, supremely confident adaptation": "Meirelles, along with screenwriter Don McKellar and cinematographer Cesar Charlone, have created an elegant, gripping and visually outstanding film. It responds to the novel's notes of apocalypse and dystopia, and its disclosure of a spiritual desert within the modern city, but also to its persistent qualities of fable, paradox and even whimsy." [37] "Blindness is a drum-tight drama, with superb, hallucinatory, images of urban collapse. It has a real coil of horror at its centre, yet is lightened with gentleness and humour. It reminded me of George A Romero's Night of the Living Dead, and Peter Shaffer's absurdist stage-play Black Comedy. This is bold, masterly, film-making."[38]

The Boston Globe's Wesley Morris raved about the leading actress: "Julianne Moore is a star for these terrible times. She tends to be at her best when the world is at its worst. And things are pretty bad in "Blindness," a perversely enjoyable, occasionally harrowing adaptation of Jos Saramago's 1995 disaster allegory. [...] "Blindness" is a movie whose sense of crisis feels right on time, even if the happy ending feels like a gratuitous emotional bailout. Meirelles ensures that the obviousness of the symbolism (in the global village the blind need guidance!) doesn't negate the story's power, nor the power of Moore's performance. The more dehumanizing things get, the fiercer she becomes."[39]

The film appeared on some critics' top ten lists of the best films of 2008. Bill White of the Seattle Post-Intelligencer named it the 5th best film of 2008,[40] and Marc Savlov of The Austin Chronicle named it the 8th best film of 2008.[40]

The film has been strongly criticized by several organizations representing the blind community. Dr. Marc Maurer, President of the National Federation of the Blind, said: "The National Federation of the Blind condemns and deplores this film, which will do substantial harm to the blind of America and the world."[41] A press release from the American Council of the Blind said "...it is quite obvious why blind people would be outraged over this movie. Blind people do not behave like uncivilized, animalized creatures."[42] The National Federation of the Blind announced plans to picket theaters in at least 21 states, in the largest protest in the organization's 68-year history.[43] Jos Saramago has described his novel as allegorically depicting "a blindness of rationality". He dismissed the protests, stating that "stupidity doesn't choose between the blind and the non-blind."[44]

In a closed section, Jos Saramago watched the movie together with Fernando Meirelles. When the movie ended, Saramago was in tears. He turned to Fernando Meirelles and said: "Fernando, I am so happy to have seen this movie as I was the day I finished the book." [45]

Read the original:
Blindness (film) - Wikipedia

Read More...

Five innovations harness new technologies for people with visual impairment, blindness – Science Daily

February 6th, 2017 9:45 am

During Low Vision Awareness Month, the National Eye Institute (NEI), part of the National Institutes of Health, is highlighting new technologies and tools in the works to help the 4.1 million Americans living with low vision or blindness. The innovations aim to help people with vision loss more easily accomplish daily tasks, from navigating office buildings to crossing a street. Many of the innovations take advantage of computer vision, a technology that enables computers to recognize and interpret the complex assortment of images, objects and behaviors in the surrounding environment.

Low vision means that even with glasses, contact lenses, medicine, or surgery, people find everyday tasks difficult to do. It can affect many aspects of life, from walking in crowded places to reading or preparing a meal, explained Cheri Wiggs, Ph.D., program director for low vision and blindness rehabilitation at the NEI. The tools needed to stay engaged in everyday activities vary based on the degree and type of vision loss. For example, glaucoma causes loss of peripheral vision, which can make walking or driving difficult. By contrast, age-related macular degeneration affects central vision, creating difficulty with tasks such as reading, she said.

Here's a look at a few NEI-funded technologies under development that aim to lessen the impact of low vision and blindness.

Co-robotic cane

Navigating indoors can be especially challenging for people with low vision or blindness. While existing GPS-based assistive devices can guide someone to a general location such as a building, GPS isn't much help in finding specific rooms, said Cang Ye, Ph.D., of the University of Arkansas at Little Rock. Ye has developed a co-robotic cane that provides feedback on a user's surrounding environment.

Ye's prototype cane has a computerized 3-D camera to "see" on behalf of the user. It also has a motorized roller tip that can propel the cane toward a desired location, allowing the user to follow the cane's direction. Along the way, the user can speak into a microphone and a speech recognition system interprets verbal commands and guides the user via a wireless earpiece. The cane's credit card-sized computer stores pre-loaded floor plans. However, Ye envisions being able to download floor plans via Wi-Fi upon entering a building. The computer analyzes 3-D information in real time and alerts the user of hallways and stairs. The cane gauges a person's location in the building by measuring the camera's movement using a computer vision method. That method extracts details from a current image captured by the camera and matches them with those from the previous image, thus determining the user's location by comparing the progressively changing views, all relative to a starting point. In addition to receiving NEI support, Ye recently was awarded a grant from the NIH's Coulter College Commercializing Innovation Program to explore commercialization of the robotic cane.

Robotic glove finds door handles, small objects

In the process of developing the co-robotic cane, Ye realized that closed doorways pose yet another challenge for people with low vision and blindness. "Finding the door knob or handle and getting the door open slows you way down," he said. To help someone with low vision locate and grasp small objects more quickly, he designed a fingerless glove device.

On the back surface is a camera and a speech recognition system, enabling the user to give the glove voice commands such as "door handle," "mug," "bowl," or "bottle of water." The glove guides the user's hand via tactile prompts to the desired object. "Guiding the person's hand left or right is easy," Ye said. "An actuator on the thumb's surface takes care of that in a very intuitive and natural way." Prompting a user to move his or her hand forward and backward, and getting a feel for how to grasp an object, is more challenging.

Ye's colleague Yantao Shen, Ph.D., University of Nevada, Reno, developed a novel hybrid tactile system that comprises an array of cylindrical pins that send either a mechanical or electrical stimulus. The electric stimulus provides an electrotactile sensation, meaning that it excites the nerves on the skin of the hand to simulate a sense of touch. Picture four cylindrical pins in alignment down the length of your index finger. One by one, starting with the pin closest to your finger tip, the pins pulse in a pattern indicating that the hand should move backward.

The reverse pattern indicates the need for forward motion. Meanwhile, a larger electrotactile system on the palm uses a series of cylindrical pins to create a 3-D representation of the object's shape. For example, if your hand is approaching the handle of a mug, you would sense the handle's shape in your palm so that you could adjust the position of your hand accordingly. As your hand moves toward the mug handle, any slight shifts in angle are noted by the camera and the tactile sensation on your palm reflects such changes.

Smartphone crosswalk app

Street crossings can be especially dangerous for people with low vision. James Coughlan, Ph.D., and his colleagues at the Smith-Kettlewell Eye Research Institute have developed a smartphone app that gives auditory prompts to help users identify the safest crossing location and stay within the crosswalk.

The app harnesses three technologies and triangulates them. A global positioning system (GPS) is used to pinpoint the intersection where a user is standing. Computer vision is then used to scan the area for crosswalks and walk lights. That information is integrated with a geographic information system (GIS) database containing a crowdsourced, detailed inventory about an intersection's quirks, such as the presence of road construction or uneven pavement. The three technologies compensate for each other's weaknesses. For example, while computer vision may lack the depth perception needed to detect a median in the center of the road, such local knowledge would be included in the GIS template. And while GPS can adequately localize the user to an intersection, it cannot identify on which corner a user is standing. Computer vision determines the corner, as well as where the user is in relation to the crosswalk, the status of the walk lights and traffic lights, and the presence of vehicles.

CamIO system helps explore objects in a natural way

Imagine a system that enables visually impaired biology students to explore a 3-D anatomical model of a heart by touching an area and hearing "aortic arch" in response. The same system could also be used to get an auditory readout of the display on a device such as a glucose monitor. The prototype system, designed with a low-cost camera connected to a laptop computer, can make physical objects -- from 2-D maps to digital displays on microwaves -- fully accessible to users with low vision or blindness.

The CamIO (short for camera input-output), also under development by Coughlan, provides real-time audio feedback as the user explores an object in a natural way, turning it around and touching it. Holding a finger stationary on 3-D or 2-D objects, signals the system to provide an audible label of the location in question or an enhanced image on a laptop screen. CamIO was conceived by Joshua Miele, Ph.D, a blind scientist at Smith-Kettlewell who develops and evaluates novel sound/touch interfaces to help people with vision loss. Coughlan plans to develop a smartphone app version of CamIO. In the meantime, software for the laptop version will be available for free download. To watch a demonstration of the CamIO system, visit http://bit.ly/2CamIO.

High-powered prisms, periscopes for severe tunnel vision

People with retinitis pigmentosa and glaucoma can lose most of their peripheral vision, making it challenging to walk in crowded places like airports or malls. People with severe peripheral field vision loss can have a residual central island of vision that's as little as 1 to 2 percent of their full visual field. Eli Peli, O.D., of Schepens Eye Research Institute, Boston, has developed lenses constructed of many adjacent one-millimeter wide prisms that expand the visual field while preserving central vision. Peli designed a high-powered prism, called a multiplexing prism that expands one's field of view by about 30 degrees. "That's an improvement, but it's not good enough," explained Peli.

In a study, he and his colleagues mathematically modeled people walking in crowded places and found that the risk of collision is highest when other pedestrians are approaching from a 45-degree angle. To reach that degree of peripheral vision, he and his colleagues are employing a periscope-like concept. Periscopes, such as those used to see the ocean surface from a submarine, rely on a pair of parallel mirrors that shift an image, providing a view that would otherwise be out of sight. Applying a similar concept, but with non-parallel mirrors, Peli and colleagues have developed a prototype that achieves a 45-degree visual field. Their next step is to work with optical labs to manufacture a cosmetically acceptable prototype that can be mounted into a pair of glasses. "It would be ideal if we could design magnetic clip-ons spectacles that could be easily mounted and removed," he said.

See more here:
Five innovations harness new technologies for people with visual impairment, blindness - Science Daily

Read More...

Arizona woman cured of blindness spreads fame of obscure Lebanese saint – Fox News

February 6th, 2017 9:45 am

The story of a Latina who regained her sight thanks to what is believed to be a miracle performed by St. Charbel, has awakened interest in the relics of this Lebanese saint being kept at a church in Phoenix, Arizona.

Dafne Gutierrez is convinced she was able to see again after she visited the relics at St. Joseph Maronite Catholic Church a year ago. So many people continue to visit the chapel since that it was decided to create a sanctuary in his honor.

The Lebanese pastor of the church, Fr. Wissam Akiki, told EFE that the construction of the sanctuary has already begun and will be shaped like a half-moon, with a large statue of the saint standing at the center.

Gutierrez, whose blindness was healed on Jan. 18, 2016, insists that what happened to her was truly a miracle.

"The doctors can't explain it. At first they thought I was imagining things because I so longed to see, but when they examined me no damage to the optic nerve was to be found," she said. "They were surprised, because according to their diagnosis, I was never going to see again, not even with a cornea transplant," she said.

Cristofer Pereyra, director of the Hispanic Office of the Phoenix Diocese, said that Bishop Thomas Olmsted himself spoke with the doctors and checked very carefully the womans case.

The bishop went to make sure there was no scientific explanation for the miraculous recovery of Dafne's sight, Pereyra said.

Fr. Akiki said that thousands of people now visit the saint's relics for their miraculous powers.

"Dafne came to confess to me, and I told her to pray and have faith. Then I made the sign of the cross on her forehead and her eyes. And then St. Charbel performed the miracle that would benefit her three children," the priest said.

The relics of St. Charbel, whose real name was Youssef Antoun Makhlouf, visited Phoenix between Jan. 15 and Jan. 17, 2016; they have toured various parishes around the country since October 2015.

In view of the great devotion of the faithful to thissaint, it was decided to leave a fragment of his hand in Phoenix,a city with a large Lebanese community.

Gutierrez, who had lived with the Arnold Chiari malformation since age 13, went blind in both eyes several years ago.

"I remember hearing on the news about a saint who did miracles, but I'd already been to so many churches I wasn't very excited about it. It was my sister-in-law who convinced me," she said.

St. Charbel died at age 70 at a Maronite monastery in Lebanon on Christmas Eve, 1898. His body lies in a tomb and was said to remain undecomposed for the greater part of a century.

The saint, who has a long history of healing the sick and disabled, even after his death, was beatified on Dec. 5, 1965, and canonized on Oct. 9, 1977, by Pope Paul VI, making him the first Lebanese saint.

See original here:
Arizona woman cured of blindness spreads fame of obscure Lebanese saint - Fox News

Read More...

Portsmouth Daily Times | Prevent Blindness declares February as … – Portsmouth Daily Times

February 6th, 2017 9:45 am

Today, more than 2 million Americans ages 50 and over have age-related macular degeneration (AMD), according to the Prevent Blindness report, Future of Vision: Forecasting the Prevalence and Costs of Vision Problems. This includes 88,546 in Ohio alone. And, the increase of the population aged 80 and older will lead to rapid growth in the AMD population over the next 20 years, reaching 3.4 million in 2032 and 4.4 million by 2050.

The Ohio Affiliate of Prevent Blindness has declared February as Age-related Macular Degeneration/Low Vision Awareness Month. AMD is a leading cause of vision loss for Americans age 50 and older. It affects central vision, where sharpest vision occurs. Almost 3 million Americans have low vision, according to the National Eye Institute.

According to the recent National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division (NASEM) consensus study, Making Eye Health a Population Health Imperative: Vision for Tomorrow, increasing age, white race, and female gender are associated with a higher risk of AMD. The report also found that a number of environmental, behavioral, genetic, and other physical conditions have been associated with the risk of AMD, including smoking, obesity and genetics.

There may be no symptoms until the disease progresses or affects both eyes, which is why regular eye exams are important. Vision changes due to AMD may include:

Prevent Blindness offers educational materials at no cost through its dedicated web pages and its toll-free number. Resources include:

Prevent Blindness AMD Learning Center- The AMD Learning Center, found at preventblindness.org/amd, provides a variety of educational tools including AMD risk factors, treatment options, an Adult Vision Risk Assessment tool, fact sheets and more.

Living Well with Low Vision- This growing online resource, lowvision.preventblindness.org, offers information ranging from an extensive list of searchable, local low vision resource directories, to an informative blog with news for people living with age-related eye disease and significant visual impairment, and their caregivers, authored by patient advocate and low vision educator Dan Roberts, M.M.E.

By detecting AMD and treating it early, vision loss can be significantly lessened, said Sherry Williams, President & CEO of Prevent Blindness, Ohio Affiliate. We urge everyone to make an appointment for a dilated eye exam today.

.

Read more here:
Portsmouth Daily Times | Prevent Blindness declares February as ... - Portsmouth Daily Times

Read More...

Government turns a Nelson’s Eye to increasing cases of blindness reported in Telangana – The New Indian Express

February 6th, 2017 9:45 am

HYDERABAD: Telangana state has 2 per cent rate of prevalence of blindness, reveals the District Level Household and Facility Survey (DLHS-4) data. This is the highest in the country.

The DLHS data clearly indicates that the state government needs to ramp up its infrastructure for controlling the increasing rate of blindness in the state.

In India, blindness is caused mainly due to two reasons: cataract and refractive errors like near and far sightedness. And both of them can be avoided if adequate healthcare is available.

The Central government, as far back as in 1976, had launched the National Programme for Control of Blindness (NPCB) for preventing occurrence of blindness.

However, thanks to the poor financial and infrastructural support from the state and following governments at the Centre, the National Programme for Control of Blindness has not been implemented efficiently and widely in the state of Telangana ever since its formulation.

State of affairs

Telangana has around 150 ophthalmic assistants today, located only in the Cluster Health Centres instead of the Primary Health Centres (PHCs). These ophthalmic assistants play a key role in implementation of the School Eye Screening programme of NPCB.

As part of the SES, the assistants prescribe glasses to students of government school aged between 10 and 14 and diagnosed with refractive error. These glasses are provided for free under the programme.

Statistically speaking, there are around 10 lakh children in the age group of 10-14 studying in government schools in the state. This means, each ophthalmic assistant has to keep track of at least 7,000 children every year. This makes it quite clear why, as per NPCB data, the state government could not achieve the target of providing glasses to 52,930 school children in the years 2014-16. They could provide glasses to around 46,000 school children.

Meanwhile, other states including Gujarat and Madhya Pradesh, for the same period, exceeded their targets providing glasses to over 2.3 lakh and 1.5 lakh children respectively.

Other issues

Lack of adequate infrastructure and expertise at district level to undertake cataract surgeries is another issue.

While Gujarat and MP conducted 16 lakh and 10 lakh cataract surgeries in 2014-16 respectively, only 10 lakh surgeries were conducted in Telangana.

NPCB officials pointed out that there has also been a delay in allotment of money by the Centre and state. The central government recently released around Rs 4 crore to NPCB in the state for the year 2016-17 and the state is yet to release its share.

Read the rest here:
Government turns a Nelson's Eye to increasing cases of blindness reported in Telangana - The New Indian Express

Read More...

The dangers of AMD; disease can cause blindness if left untreated … – KHON2

February 6th, 2017 9:45 am

It strikes like a thief in the night.

The disease, if left untreated, can slowly steal your central vision, leaving you blind for the rest of your life.

Age-related macular degeneration (AMD) affects more than 10 million people in the U.S.

This is the most common cause of vision loss that is not correctable by lenses or cataract surgery, and is very common in the 80-plus group. Fifty percent of my patients have that disease, said ophthalmologist Dr. Malcolm Ing. That occurs at the back of the eye, right near the optic nerve, right where my finger is. That is the macular, and that is the area that deteriorates.

Patients may notice blacking or graying out at the central part of their vision while reading.

Patients with dry AMD receive antioxidants as treatment.Those with Wet AMD are at higher risk of going blind and must receive injections directly into the eyes every six weeks.

Its a downhill slide right away if you see hemorrhages in the macular, Ing said. If left untreated, you can go blind within a week.

One way to avoid this is to not smoke.

For instance, if you smoke, you have four times the incidents four times 400 percent increase in macular degeneration, Ing explained.

Controlling your weight also helps.

We found that you have a big opu, like some of the people have in our kupuna group, then you increase your incidents by 200 percent, so twice as likely to have that problem, Ing said.

Belly fat produces inflammatory chemicals that target our eyes and brain. Eating fish can reduce risk of AMD by 40 percent, and so can eating green leafy vegetables.

Eat your spinach, because it has green leafy vegetables, and green leafy vegetables has nutrients that help protect the retina, Ing said.

February is AMD Awareness Month, another reason to see your eye doctor regularly.

Click here for more information about AMD from the National Eye Institute.

Go here to read the rest:
The dangers of AMD; disease can cause blindness if left untreated ... - KHON2

Read More...

Malin stakes 32% take in US biotechnology company Artizan – Irish Times

February 6th, 2017 9:45 am

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota.

Irish based life sciences company Malin said on Monday that it has acquired a 32 per cent shareholding of US biotechnology company Artizan Biosciences.

Dublin-based Malin, which has invested more than 300 million in life sciences companies since it was established in early 2015, invested in Artizan via a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership.

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota. It was spun out of Yale University and established as a standalone business in 2016 and its founders include Prof. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD, from Yale University. Artizan, which aims to be a leader in the microbiota-driven inflammatory diseases space, has developed a capability of distinguishing certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for any number of digestive disorders as well as other diseases including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system (CNS) diseases.

Artizans proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders, Adrian Howd, chief investment officer of Malin, said.

Last month Malin acquired a 33 per cent shareholding of Wren Therapeutics, a newly created biopharmaceutical company based in Cambridge, UK. It was set up by a number of former Elan executives in 2015.

Read more from the original source:
Malin stakes 32% take in US biotechnology company Artizan - Irish Times

Read More...

Opinion: Harry Boxer: Watch these two biotechnology stocks – MarketWatch

February 6th, 2017 9:45 am

President Trump pressed Big Pharma executives to increase U.S. production and lower drug prices.

As biotechnology stocks have been showing momentum following a meeting between President Trump and pharmaceutical executives Tuesday, our two long investments to watch are in that sector. There are also several shorts among our charts to watch to play the potential downside in this near-term, toppy-looking stock market.

Gene-therapy company bluebird bio Inc. BLUE, -2.10% has a strong-looking chart. The stock recently broke out of a wedge pattern, in which its price range had narrowed for two months in essentially a sideways direction. The stock continued the upmove on Tuesday when it popped $5.90, or over 8%, to $74.50, and followed through for another $1.10 on Wednesday to $75.60. The stock is now positioned to challenge its recent high at $79.70 from early December. A break through there could lead to a move into the mid-$80s, followed by a next target in the mid-$90s. With short interest of 9.2 its average volume, the price advance could be further fueled by short covering.

Cara Therapeutics Inc. CARA, -0.90% a cannabis-based biotech, has been steadily climbing since the start of the year. On Wednesday, the stock popped $1.17, or 7.6%, to $16.49 on 4.7 million shares, which is huge volume for this stock, the biggest since mid-November. The stock got as high as $17.20 intraday before pulling back into the close. It is a bit extended near the top of its channel and could pull back and consolidate before its next move, but momentum could carry it a bit further toward $18.

On the short side, Carters Inc. CRI, +0.26% continues lower since its July 2016 top above $112. On Wednesday, shares in the childrens wear retailer were down another $1.05, or 1.3%, to $82.70, on 690,100 shares traded. The stock appears headed toward the bottom of its declining channel in the $73-$74 range.

Signet Jewelers Ltd. SIG, -0.67% is also continuing lower. The stock rallied from the bottom of its declining price channel to the top in the last quarter of 2016, but has since broken down. Shares fell another 66 cents to $77.01 on 1.5 million shares traded on Wednesday. Watch for a test of the late-September low in the $72-$73 range. A takeout of that could drop the stock near its channel bottom in the low- to mid-$60s.

See Harrys video chart analysis on these and other stocks.

The writer has no holdings in any securities mention in this article.

Harry Boxer is the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

Follow this link:
Opinion: Harry Boxer: Watch these two biotechnology stocks - MarketWatch

Read More...

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil – National Catholic Register

February 6th, 2017 9:45 am

Commentary | Feb. 3, 2017

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil

Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination?

Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread.

Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology.

The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly.

Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued to divide, but not for long.All of the embryos were to be destroyedbefore they are 15 days old,as the law in Sweden dictates. Lanner insists that his research is critical to understanding human development, which, in turn, will shed light on infertility and disease.

Lanners work makes many ethicists and scientists extremely nervous. Jennifer Doudna, the co-inventor of CRISPR, along with other heavy-hitting scientists,havecalled for a voluntary moratorium on any editing of human embryosfor fear that it will lead to the creation of genetically modified children. Marcy Darnovsky, of the left-leaning Center for Genetics and Society, explains why she and her group havebeen so vocal in their opposition to the modification of human embryos. She told NPR: The production of genetically modified human embryos is actually quite dangerous. ... When youre editing the genes of human embryos, that means youre changing the genes of every cell in the bodies of every offspring, every future generation of that human being. So these are permanent and probably irreversible changes that we just dont know what they would mean.

Then came the revelation that a U.S. doctor traveled to Mexico to create the first baby intentionally engineered to have three genetic parents. This technique, misnamed mitochondrial replacement or MR, seeks to eliminate the transmission of genetic disease through the mitochondria.Mitochondria are small but abundant organellesoutside the nucleusinthe cytoplasmof our cells that make energy. They have their own DNA called mtDNA. We inherit our mtDNA solely from our mothers. A woman who carries a deleterious mutation in her mtDNA cannot help but pass that on to her offspring.

There are various MR techniques that replace the mitochondria of a woman with mitochondrial disease with the mitochondria of a donor femalein the IVF process.Essentially, MR creates a genetically alteredembryo with the genetic material from three people, one man and two women.

MR had only undergone limited study in primates before getting approval in the United Kingdom for use in fertility clinics to make babies. Little is known about the complexcommunication between the DNA in the nucleus and the DNA in the mitochondria,and so there is little data on the effects ofa mismatch between the nuclear DNA and mtDNA.

Alsoin all MR, its the nucleus thats being moved from cell to cell, not the mitochondria which is why mitochondrial replacement is such a misnomer.This makes MR acousin to cloning, which also transplants the nucleus of one cell into anotherto make a new organism. MR brings with it many of the same risks.Scientists are concerned about the health of the resulting children.

In anopen letterto the U.K. Parliament, Dr. Paul Knoepfler, a vocal American stem-cell researcher, warned: Even if, hypothetically, this technology might help avoid some people from having mitochondrial disorders (and thats a big if), the bottom line is that there is an equal or arguably greater chance that it will tragically produce very ill or deceased babies.

MRis also a germ-line genetic modification, which means that any girl born with this technique will pass her genetic modification on to her children.

A recent review in Nature reveals that MR leaves a tiny percentage of mutant mitochondria behind, and sometimes the mutant mitochondria rapidly divide and overtake the healthy mitochondria. Shoukhrat Mitalipov, head of the Center for Embryonic Cell and Gene Therapy at the Oregon Health and Science University, reported a 15% failure rate where mitochondrial defects returned. Mitalipov told NPR, That original, maternal mitochondrial DNA took over, and it was pretty drastic. There was less than 1% of the original maternal mitochondrial DNA present after replacement with donor DNA and before fertilization, and yet it took over the whole cell later. University of California San Francisco professor Patrick OFarrell suggests that mutant mitochondria can resurge at any time in a developing three-parent child or even resurface in future generations.

For all these reasons, MR is not yet approved by the FDA in the United States,and may never be.So, when a Jordanian woman with mitochondrial disease wanted to have a child using MR, John Zhang, from the New Hope Fertility Center in New York City, had to perform the procedure in Mexico. He created five embryos,and, according toNewScientist.com,only one developed normally. That child is now 9 months old.

Zhang went to Mexico because, he said, there are no rules, and yet he insists he did the safe and ethical thingin the absence of any medical or ethical oversight. In an ironic twist, the couple is Muslim and so chose the MR technique that wouldnt destroy existing embryos.But it was clear that only male embryos would be transferred for gestation, because boys cant pass on the genetic modification. What happened to the other four embryos, however? Were they destroyed,discarded or frozen? If they were females, would they have been destroyed anyway to make sure they couldnt pass on any ill effects?

Darnovskycalledthis rogue experimentationand added, No researcher or doctor has the right to flout agreed-upon rules and make up their own. This is an irresponsible and unethical act.

Knoepflerrespondedto the news by remindingus that this is a living human experiment that is going to unfold over years and decades. It is also worth noting that this child is a genetically modified human being as a result of this technique.

Of course, these are happenings to despair of not only because of the sheer disregard for the sanctity of individual human lives, but because of the breakneck speed at which scientists are kicking ethical lines farther and farther down the road like a tin can. All the while, they insist that its for the good of humanity. I wonder: How can wetreatindividual members of the human species so callously and then, at the same time, say its for the good of the whole human race?

I fear there is no line we wont cross;no ethical boundary wewonttear down in the name of science.

On a daily basis, Im surrounded by science and scientists. Often, their response to this madness is that its going to happen anyway, and theres no way to stop it, which implies we must go along to get along all in the name of progress.

If I am Frodo, then they and the rest of society are Saruman giving in to the despair and making a deal with Sauron.In the film version of The Lord of the Rings, Saruman says to Gandalf: Against the power of Mordor there can be no victory. We must join with him, Gandalf. We must join with Sauron. It would be wise, my friend.

Gandalf replies, Tell me, friend, when did Saruman the Wise abandon reason for madness?

Indeed. When did science abandon reason for madness, ethics for recklessness?

So what shall we do? If wesuccumb to despair, we become like Saruman.

We always have prayer. Its time toadd human embryonic research and germ-line human genetic engineering to our list of life issues that we pray about.It doesnt matter whether we understand the finer points of the science or not.Praying for an end to abortion andassisted suicide is nolongerenough.

In addition to prayer, there are other things we can do. The first is to vote pro-life at every level of government, from city council to state assemblymen. Being pro-life isnt just about abortion, however. Its about protecting the sanctity of life from the beginning to the end. Pro-life legislators, even if they cannot overturn Roe v. Wade, can effect local and state laws and steer funding away from unethical research.

Secondly, we must fight for conscience rights for medical professionals. I envision a not-so-far-off world wheredoctorsare forced into making genetically engineered embryos and bringing these children to term simply because parents claim its their reproductive right to have the children of their design. Without conscience rights, unethical experimentation on the next generation will be rampant and unchecked.

We must, however, always have hope. Whenstaring downthe juggernaut that is modern biotechnology, I always remember Frodo Baggins.When he was faced with the seemingly impossible task of taking the One Ring to Mordor, instead of shying away because it was too hard, he said: I will take the Ring, though I do not know the way.

Rebecca Tayloris a

clinical laboratory specialist in molecular biology.

She writes about bioethics on her blog,Mary Meets Dolly.

Excerpt from:
Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil - National Catholic Register

Read More...

More Volatility Ahead for Biotechnology Sector – Wall Street Journal (blog)

February 6th, 2017 9:45 am
More Volatility Ahead for Biotechnology Sector
Wall Street Journal (blog)
After underperforming the S&P 500 over the past six months, the biotechnology sector is poised for more volatility ahead. The group drew plenty of attention on the campaign trail as both and Democratic candidate criticized the high prices for drugs ...

Link:
More Volatility Ahead for Biotechnology Sector - Wall Street Journal (blog)

Read More...

Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) – The Independent Republic

February 6th, 2017 9:45 am

Intrexon Corporation (XON) ended last trading session with a change of 5.25 percent. It trades at an average volume of 1.33M shares versus 1.7M shares recorded at the end of last trading session. The share price of $22.04 is at a distance of 8.09 percent from its 52-week low and down -45.23 percent versus its peak. The company has a market cap of $2.61B and currently has 118.35M shares outstanding. The share price is currently -5.82 percent versus its SMA20, -16.17 percent versus its SMA50, and -17.92 percent versus its SMA200. The stock has a weekly performance of 2.04 percent and is -9.3 percent year-to-date as of the recent close.

Jan. 26, 2017 Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle cell disease as part of a national resource that could lead to new treatments for the disorder.

The subcontract is with Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, part of the National Institutes of Health (NIH). Work under the subcontract will support the NIHs National Center for Advancing Translational Sciences (NCATS) in creating genetically engineered miniswine models of sickle cell disease. Exemplar Genetics will develop several versions of genetically engineered miniswine models of sickle cell disease that more accurately replicate the human pathology as compared to traditional research models.

Keryx Biopharmaceuticals, Inc. (KERX) recently recorded -0.55 percent change and currently at $5.45 is 75.24 percent away from its 52-week low and down -30.13 percent versus its peak. It has a past 5-day performance of 13.54 percent and trades at an average volume of 1.61M shares. The stock has a 1-month performance of -12.38 percent and is -7 percent year-to-date as of the recent close. There were about 106.55M shares outstanding which made its market cap $580.7M. The share price is currently -1.7 percent versus its SMA20, -5.27 percent versus its SMA50, and -1.49 percent versus its SMA200.

Nov. 18, 2016 Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced case study data, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation at the American Society of Nephrologys 2016 Kidney Week taking place in Chicago.

The rest is here:
Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) - The Independent Republic

Read More...

2 Sizzling Hot Biotechnology Stocks: Achillion Pharmaceuticals, Inc. (ACHN), Stemline Therapeutics, Inc. (STML) – The Independent Republic

February 6th, 2017 9:45 am

Achillion Pharmaceuticals, Inc. (ACHN) ended last trading session with a change of 2.61 percent. It trades at an average volume of 2.22M shares versus 1.78M shares recorded at the end of last trading session. The share price of $4.32 is at a distance of 14.29 percent from its 52-week low and down -57.06 percent versus its peak. The company has a market cap of $575.38M and currently has 133.19M shares outstanding. The share price is currently 2.99 percent versus its SMA20, 3.06 percent versus its SMA50, and -38.89 percent versus its SMA200. The stock has a weekly performance of 5.62 percent and is 4.6 percent year-to-date as of the recent close.

On Dec. 28, 2016 Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 Phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection (HCV) without cirrhosis.

We are delighted to have reached this milestone following Janssens recent initiation of the OMEGA-1 global clinical trial evaluating JNJ-4178, a once-daily combination of AL-335, simeprevir, and the Achillion-discovered NS5A inhibitor, odalasvir, and we look forward to JNJ-4178s continued clinical advancement, commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion.

Stemline Therapeutics, Inc. (STML) recently recorded 16.96 percent change and currently at $6.55 is 68.81 percent away from its 52-week low and down -55.14 percent versus its peak. It has a past 5-day performance of -35.78 percent and trades at an average volume of 285.02K shares. The stock has a 1-month performance of -44.96 percent and is -38.79 percent year-to-date as of the recent close. There were about 20.21M shares outstanding which made its market cap $132.38M. The share price is currently -41.5 percent versus its SMA20, -44.82 percent versus its SMA50, and -29.73 percent versus its SMA200.

Feb. 02, 2017 Stemline Therapeutics, Inc. (STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its ongoing pivotal Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN), using Stemlines experimental compound, SL-401. BPDCN at present has no approved treatment.

On January 18, the Company received a report that a patient death had occurred. The patient had developed capillary leak syndrome (CLS), a known, sometimes fatal, and well-documented side effect of SL-401. The cause of the patients death has not yet been determined. The safety profile for SL-401 includes CLS, and there have been previous deaths reported in patients with CLS in this trial, which have been disclosed in public presentations. That CLS is an expected complication of the administration of SL-401 has also been identified in filings with the Securities and Exchange Commission (SEC) and U.S. Food and Drug Administration (FDA), as well as in the studys informed consent forms and other information provided to investigators.

See the article here:
2 Sizzling Hot Biotechnology Stocks: Achillion Pharmaceuticals, Inc. (ACHN), Stemline Therapeutics, Inc. (STML) - The Independent Republic

Read More...

Two Biotechnology Names Are Hot: Celldex Therapeutics, Inc. (CLDX), Eleven Biotherapeutics, Inc. (EBIO) – The Independent Republic

February 6th, 2017 9:45 am

Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 2.08 percent. It trades at an average volume of 2.28M shares versus 1.33M shares recorded at the end of last trading session. The share price of $3.43 is at a distance of 20.35 percent from its 52-week low and down -60.8 percent versus its peak. The company has a market cap of $340.19M and currently has 99.18M shares outstanding. The share price is currently -2.15 percent versus its SMA20, -7.49 percent versus its SMA50, and -13.68 percent versus its SMA200. The stock has a weekly performance of 1.48 percent and is -3.11 percent year-to-date as of the recent close.

On Dec. 14, 2016 Celldex Therapeutics, Inc. (CLDX) announced the appointment of Gerald McMahon, Ph.D., to the Companys Board of Directors. Dr. McMahon was previously the President and Chief Executive Officer of Kolltan Pharmaceuticals. In addition, the Company announced that Richard van den Broek has resigned from the Board due to increasing responsibilities in other endeavors.

Dr. McMahon brings an exceptional background in science and drug development, particularly in the oncology space, to the Celldex Board, said Larry Ellberger, Chairman of the Board of Directors at Celldex Therapeutics. We believe he will be a valuable addition as we advance a robust pipeline, which now also includes drug candidates targeting receptor tyrosine kinases, an area of expertise for Jerry. I would also like to recognize Rich for his contributions to Celldex. We wish him all the best in his future endeavors.

Eleven Biotherapeutics, Inc. (EBIO) recently recorded 4.61 percent change and currently at $2.27 is 804.38 percent away from its 52-week low and down -61.98 percent versus its peak. It has a past 5-day performance of 4.13 percent and trades at an average volume of 1.15M shares. The stock has a 1-month performance of -1.73 percent and is 18.85 percent year-to-date as of the recent close. There were about 23.17M shares outstanding which made its market cap $52.6M. The share price is currently 5.56 percent versus its SMA20, 4.83 percent versus its SMA50, and -9.19 percent versus its SMA200.

On November 14, 2016 Eleven Biotherapeutics, Inc. (EBIO) reported financial results for the third quarter ended September 30, 2016, and recent business highlights.

This is an exciting period for Eleven. We completed the Roche licensing deal, including $30 million in upfront and milestone payments received to date. We also completed the acquisition of Viventia Bio Inc. which allowed us to become a late-stage oncology company. Perhaps most excitingly, we are making significant progress in moving forward what we believe could be therapeutics that materially improve patients lives. We anticipate complete enrollment in the first half of next year for our Phase 3 clinical trial of Vicinium as a potential treatment for high-grade non-muscle invasive bladder cancer, and expect topline data in the first half of 2018, said Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics. We also plan to initiate our Phase 2 trial in late-stage squamous cell carcinoma of the head and neck with Proxinium in combination with a checkpoint inhibitor in the first half of 2017. Also in 2017, we plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin. With the combined expertise of Eleven and the Viventia team, I am very excited about the opportunities we have ahead.

Go here to read the rest:
Two Biotechnology Names Are Hot: Celldex Therapeutics, Inc. (CLDX), Eleven Biotherapeutics, Inc. (EBIO) - The Independent Republic

Read More...

Rheumatoid arthritis and feet: The connection and feet arthritis pain relief tips – Bel Marra Health

February 6th, 2017 9:44 am

Home Anti-Aging Arthritis Rheumatoid arthritis and feet: The connection and feet arthritis pain relief tips

Rheumatoid arthritis is a chronic disease involving the immune system, in which joints undergo inflammation. causing pain and stiffness.People with rheumatoid arthritis generally find difficulty performing simple movements that involve the joints, such as walking, standing up, and sitting down.

This condition has also affected individual performance at work or school, prompting the medical field to identify an effective treatment. Having this inflammatory condition affecting the joints may also be responsible for certain emergency visits to the hospital, especially when a person suffers from a decreased ability to operate a motor vehicle or machine. In other cases, visits to the emergency room may be due to extreme pain experienced by a patient with rheumatoid arthritis.

Common treatment plans for rheumatoid arthritis include anti-inflammatory drugs, such as aspirin, ibuprofen, and naproxen. It is also possible to prescribe disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis, although this type of treatment may also increase the risk of developing severe side effects, which may also require emergency medical attention. More recent improvements in treatment include the use of biologics, which are proteins that influence the immune system to slow down the progression of rheumatoid arthritis.

In extreme cases of rheumatoid arthritiswhere drug treatment appears to be ineffectivesurgery may also be recommended. It is important to understand that this disorder involves the immune system and the joints, and may also decrease the ability of a person to move. Many emergency calls involving the elderly are caused by rheumatoid arthritis increasing slips and falls.

Based on the severity of rheumatoid arthritis and its association with emergency medical treatments caused by accidents, health groups and researchers have looked into specific signs and symptoms that could be detected at an early stage. Using this information, people who are at a higher risk of developing rheumatoid arthritis may be educated on how to maintain their healthy bodies at an earlier age and possibly prevent the development of this immune system-related inflammatory disease. This information may also decrease the incidence of emergency visits to the hospital and ultimately lower the need for aggressive treatment of the disease.

According to a recent medical report, the features of the feet may serve as a reliable indicator for signs of rheumatoid arthritis at its early stages and the condition of an individuals immune system. For example, the ankle is composed of several joints and generally responsible for the stability of the body while standing upright. Any signs of stiffness, swelling, and pain in the ankle may indicate that this foot area may need emergency treatment in order to prevent further deterioration.

The report presented the findings of 100 individuals with rheumatoid arthritis who were interviewed during their earlier stages of the disease. The results of the study showed that the earliest symptoms of foot problems involved the ankle, followed by the forefoot. Years after, these individuals also experienced pain and stiffness in the hindfoot and midfoot. The study participants also admitted that they used insoles as primary treatment of the pain they encounter in their feet. The report also showed that aside from early foot problems, these patients also presented higher body weight, so it is possible that the rheumatoid arthritis development was faster due to this specific feature.

This recent medical report provides direct proof that certain foot features could serve as indicators of rheumatoid arthritis.

Below are some tips that may help you manage foot pain caused by arthritis. Be sure to check with your doctor before making any changes to your pain relief regimen.

Visit your doctor: The first step in seeking pain relief should always be to see your doctor to obtain a proper diagnosis. Your family doctor can refer you to a podiatrist or rheumatologist, who will check your feet annually to look for signs of arthritis and evaluate if any medications or exercise regimens are working.

Pick the right shoes: Ensure that your shoes have arch support, are wide enough for your feet, and are comfortable enough to minimize any pain you may feel. Toning athletic shoes with rocker bottoms are a good choice for a supportive, comfortable shoe.

Stretch: Stretching your Achilles tendons, along with the tendons in the balls of your feet and toes, can help improve joint mobility and relieve pain.

Get a foot massage: A foot massage that focuses on the balls of your feet and your toes can help relax the muscles in your feet and provide pain relief.

Topical ointments: Ointments that contain capsaicin can help reduce inflammation when applied topically to problem areas. Try using one of these creams or ointments on your feet for arthritis pain relief.

Related: Rheumatoid arthritis (RA): Causes, symptoms, and treatment

Related Reading:

Rheumatoid arthritis patients are at a higher risk for heart failure: Study

Rheumatoid arthritis and skin problems: Causes and treatment

See the original post:
Rheumatoid arthritis and feet: The connection and feet arthritis pain relief tips - Bel Marra Health

Read More...

Local woman honored for arthritis advocacy – Brainerd Dispatch

February 6th, 2017 9:44 am

For more than 8 years, Sundquist has been learning to manage and overcome juvenile rheumatoid arthritisa diagnosis she received when she was 7 years old, according to a news release. Now, as a young adult, she is becoming an outspoken advocate for the Arthritis Foundation.

As the Arthritis Foundation's signature, national fundraising event, the Walk to Cure Arthritis brings together communities to fight arthritis and is a great way to experience the power of giving back to your community. The local Walk to Cure Arthritis is May 20 at the Paul Bunyan Trailhead in Baxter. For more information, visit http://www.walktocurearthritis.org/northernlakes or call Brekka Nessler at 651-229-5368.

In the United States, more than 50 million adults and 300,000 children live with arthritis and it affects one in five Americans. The Walk to Cure Arthritis will help those living with arthritis by supporting programs, research and advocacy initiatives as well as fund crucial research aimed at finding a cure for the disease.

View original post here:
Local woman honored for arthritis advocacy - Brainerd Dispatch

Read More...

Page 1,100«..1020..1,0991,1001,1011,102..1,1101,120..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick